Search results
Results from the WOW.Com Content Network
Following infection with HIV, the rate of clinical disease progression varies enormously between individuals. Many factors such as host susceptibility and immune function, [ 2 ] [ 3 ] [ 4 ] health care and co-infections, [ 5 ] [ 6 ] [ 7 ] as well as factors relating to the viral strain [ 8 ] [ 9 ] may affect the rate of clinical disease ...
The combination of Rekambys and Vocabria injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml) with their current ARV treatment, and when the virus has not developed resistance to certain class of anti-HIV medicines called non-nucleoside reverse transcriptase ...
WHO Disease Staging System for HIV Infection and Disease was first produced in 1990 by the World Health Organization [1] and updated in 2007. [2] It is an approach for use in resource limited settings and is widely used in Africa and Asia and has been a useful research tool in studies of progression to symptomatic HIV disease .
Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring. It should be contrasted with pre-exposure prophylaxis , which is used before the patient has been exposed to the infective agent.
Figure 1. Early Symptoms of HIV. The stages of HIV infection are acute infection (also known as primary infection), latency, and AIDS.Acute infection lasts for several weeks and may include symptoms such as fever, swollen lymph nodes, inflammation of the throat, rash, muscle pain, malaise, and mouth and esophageal sores.
Acquired immunodeficiency syndrome (AIDS) is defined as an HIV infection with either a CD4 + T cell count below 200 cells per μL or the occurrence of specific diseases associated with HIV infection. [32] In the absence of specific treatment, around half of people infected with HIV develop AIDS within ten years. [32]
HIV encephalopathy; The presumptive criteria are designed for use where access to confirmatory diagnostic testing for HIV infection by means of virological testing (usually nucleic acid testing, NAT) or P24 antigen testing for infants and children aged under 18 months is not readily available.
Lamivudine (Epivir) is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection. [4] [6] Lamivudine (Epivir HBV) is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. [5] [7]